Autolus Therapeutics Stock Piotroski F Score
| AUTL Stock | USD 4.21 0.27 6.03% |
Autolus | Piotroski F Score |
At this time, it appears that Autolus Therapeutics' Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
2.0
Piotroski F Score - Frail
| Current Return On Assets | Negative |
| Change in Return on Assets | Decreased |
| Cash Flow Return on Assets | Negative |
| Current Quality of Earnings (accrual) | Improving |
| Asset Turnover Growth | Decrease |
| Current Ratio Change | Decrease |
| Long Term Debt Over Assets Change | N/A |
| Change In Outstending Shares | Increase |
| Change in Gross Margin | No Change |
Autolus Therapeutics Piotroski F Score Drivers
The critical factor to consider when applying the Piotroski F Score to Autolus Therapeutics is to make sure Autolus is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Autolus Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Autolus Therapeutics' financial numbers are properly reported.
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0043 | 0.0045 |
|
| |||||
| Total Current Liabilities | 24.3 M | 21.1 M |
|
| |||||
| Non Current Liabilities Total | 264.6 M | 252 M |
|
| |||||
| Total Assets | 279.3 M | 254.2 M |
|
| |||||
| Total Current Assets | 231.8 M | 233 M |
|
|
Autolus Therapeutics F Score Driver Matrix
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Autolus Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Autolus Therapeutics in a much-optimized way.
Click cells to compare fundamentals
About Autolus Therapeutics Piotroski F Score
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.Book Value Per Share |
|
About Autolus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Autolus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Autolus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Autolus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Autolus Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Autolus Therapeutics' short interest history, or implied volatility extrapolated from Autolus Therapeutics options trading.
Pair Trading with Autolus Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Autolus Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Autolus Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Autolus Stock
| 0.67 | ELYM | Eliem Therapeutics | PairCorr |
| 0.58 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.51 | NRSNW | NeuroSense Therapeutics | PairCorr |
| 0.47 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.41 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Autolus Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Autolus Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Autolus Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Autolus Therapeutics to buy it.
The correlation of Autolus Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Autolus Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Autolus Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Autolus Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Autolus Therapeutics Altman Z Score, Autolus Therapeutics Correlation, Autolus Therapeutics Valuation, as well as analyze Autolus Therapeutics Alpha and Beta and Autolus Therapeutics Hype Analysis. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Complementary Tools for Autolus Stock analysis
When running Autolus Therapeutics' price analysis, check to measure Autolus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Autolus Therapeutics is operating at the current time. Most of Autolus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Autolus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Autolus Therapeutics' price. Additionally, you may evaluate how the addition of Autolus Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is Autolus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.20) | Revenue Per Share 0.01 | Quarterly Revenue Growth (1.00) | Return On Assets (0.25) | Return On Equity (1.02) |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.